These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19115380)

  • 1. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
    Sagredo O; González S; Aroyo I; Pazos MR; Benito C; Lastres-Becker I; Romero JP; Tolón RM; Mechoulam R; Brouillet E; Romero J; Fernández-Ruiz J
    Glia; 2009 Aug; 57(11):1154-67. PubMed ID: 19115380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
    Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
    ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
    Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
    Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
    Lastres-Becker I; Bizat N; Boyer F; Hantraye P; Brouillet E; Fernández-Ruiz J
    Neuroreport; 2003 May; 14(6):813-6. PubMed ID: 12858038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.
    Valdeolivas S; Pazos MR; Bisogno T; Piscitelli F; Iannotti FA; Allarà M; Sagredo O; Di Marzo V; Fernández-Ruiz J
    Cell Death Dis; 2013 Oct; 4(10):e862. PubMed ID: 24136226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
    Alfinito PD; Wang SP; Manzino L; Rijhsinghani S; Zeevalk GD; Sonsalla PK
    J Neurosci; 2003 Nov; 23(34):10982-7. PubMed ID: 14645494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat.
    Armentero MT; Fancellu R; Nappi G; Blandini F
    Exp Neurol; 2002 Dec; 178(2):301-5. PubMed ID: 12504889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of malonate-induced GABA but not dopamine loss by GABA transporter blockade in rat striatum.
    Zeevalk GD; Manzino L; Sonsalla PK
    Exp Neurol; 2002 Jul; 176(1):193-202. PubMed ID: 12093096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
    J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid CB2 receptor stimulation attenuates brain edema and neurological deficits in a germinal matrix hemorrhage rat model.
    Tao Y; Tang J; Chen Q; Guo J; Li L; Yang L; Feng H; Zhu G; Chen Z
    Brain Res; 2015 Mar; 1602():127-35. PubMed ID: 25625355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
    Xia XG; Schmidt N; Teismann P; Ferger B; Schulz JB
    J Neurochem; 2001 Oct; 79(1):63-70. PubMed ID: 11595758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease.
    Toulmond S; Tang K; Bureau Y; Ashdown H; Degen S; O'Donnell R; Tam J; Han Y; Colucci J; Giroux A; Zhu Y; Boucher M; Pikounis B; Xanthoudakis S; Roy S; Rigby M; Zamboni R; Robertson GS; Ng GY; Nicholson DW; Flückiger JP
    Br J Pharmacol; 2004 Feb; 141(4):689-97. PubMed ID: 14744804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
    Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
    Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CB2 receptors in neuroprotective effects of cannabinoids.
    Fernández-Ruiz J; Pazos MR; García-Arencibia M; Sagredo O; Ramos JA
    Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S91-6. PubMed ID: 18291574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor 2 activation restricts fibrosis and alleviates hydrocephalus after intraventricular hemorrhage.
    Tan Q; Chen Q; Feng Z; Shi X; Tang J; Tao Y; Jiang B; Tan L; Feng H; Zhu G; Yang Y; Chen Z
    Brain Res; 2017 Jan; 1654(Pt A):24-33. PubMed ID: 27769788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system in Huntington's disease.
    Pazos MR; Sagredo O; Fernández-Ruiz J
    Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia.
    Molina-Holgado F; Pinteaux E; Moore JD; Molina-Holgado E; Guaza C; Gibson RM; Rothwell NJ
    J Neurosci; 2003 Jul; 23(16):6470-4. PubMed ID: 12878687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.